Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jpinkmanon Oct 25, 2021 9:04am
297 Views
Post# 34043995

HERE'S THE LETTER

HERE'S THE LETTERrelated to the nr out this morn. in the VPT news above.

Dear Friend;
 
This news article was released this morning.  Here is some background:
 
1.    Fiona is a season life sciences executive with international experience in Canada, the USA and Europe.
2.    She began her career in technology transfer at Cambridge, UK.
3.    She has spent decades on sales and marketing and operations for GEHC.
4.    Her division at GEHC, now called Cytiva, was purchased by Danaher Corporation (NYSE:DHR) last year and added to their many operating companies.
5.    Fiona was awarded the GEHC Leadership Excellence Award in 2008, and was nominated for an Echo Award in 2004, which is a marketing campaign award for a frequent buyer campaign she established in the United States.
6.    She continues her strong ties to GEHC by mentoring women within GEHC on their career paths.
7.    We are thrilled to have her join the Board of Directors.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
www.ventripoint.com
519-803-6937
 

<< Previous
Bullboard Posts
Next >>